<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098630</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1596065</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Reduced immune response to SARS-CoV-2 infection in the elderly after 6 months</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Qin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Song</surname><given-names>Qinqin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Yan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/></contrib><contrib contrib-type="author"><name><surname>Zong</surname><given-names>Kexin</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ti</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1990566/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Junming</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1209817/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/></contrib><contrib contrib-type="author"><name><surname>Mei</surname><given-names>Guoyong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Haijun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Zhiqiang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Mi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Juan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Chen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1653696/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Dong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Guangyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Wenyan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Yinli</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kou</surname><given-names>Zengqiang</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dong</surname><given-names>Zhongjun</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/964003/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Han</surname><given-names>Jun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/400400/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Shandong Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Intelligent Monitoring, Early Warning, and Prevention and Control of Infectious Diseases, Shandong Institute of Preventive Medicine</institution>, <addr-line>Jinan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Infectious Diseases, The First Affiliated Hospital of Xi&#x02019;an Jiaotong University</institution>, <addr-line>Xi&#x02019;an</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>The First Affiliated Hospital of Anhui Medical University and Institute of Clinical Immunology, Anhui Medical University</institution>, <addr-line>Hefei</addr-line>, <country>China</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>State Key Laboratory of Membrane Biology, School of Medicine and Institute for Immunology, Tsinghua University</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Juan Bautista De Sanctis, Palack&#x000fd; University Olomouc, Czechia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Alexis Hip&#x000f3;lito Garc&#x000ed;a, Central University of Venezuela, Venezuela</p><p>Flor Pujol, Instituto Venezolano de Investigaciones Cient&#x000ed;ficas (IVIC), Venezuela</p></fn><corresp id="fn001">*Correspondence: Jun Han, <email xlink:href="mailto:hanjun_sci@163.com">hanjun_sci@163.com</email>; Zhongjun Dong, <email xlink:href="mailto:dongzj@mail.tsinghua.edu.cn">dongzj@mail.tsinghua.edu.cn</email>; Zengqiang Kou, <email xlink:href="mailto:jack-cou@163.com">jack-cou@163.com</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1596065</elocation-id><history><date date-type="received"><day>19</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Luo, Song, Li, Zong, Liu, He, Mei, Du, Xia, Liu, Song, Gao, Xia, Xue, Tian, Qu, Kou, Dong and Han</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Luo, Song, Li, Zong, Liu, He, Mei, Du, Xia, Liu, Song, Gao, Xia, Xue, Tian, Qu, Kou, Dong and Han</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objectives</title><p>To evaluate the immune persistence and cross-immune response of elderly individuals after Omicron BA.5 infections.</p></sec><sec><title>Method</title><p>The neutralizing antibodies against WT, BA.5, XBB.1 and EG.5 strains were analyzed. The T/B-cell subsets&#x02019; responses were tested through intracellular cytokine staining and flow cytometry.</p></sec><sec><title>Results</title><p>The neutralizing antibodies titers against WT and BA.5 strain, remaining high level for at least 6 months, were higher than that of both XBB.1 and EG.5 variants. The neutralizing antibodies of WT, BA.5, XBB.1, and EG.5 strains in the elderly were slightly lower than those in middle-age. The memory B cells decreased rapidly in the elderly, and Tfh, Th17 cells of the elderly continued to increase for only 3 months, while Tfh and Th17 cells increased in the middle-aged for over 6 months. For the elderly, after peptide stimulation, unswitched/switched memory B cells decreased, while double negative B cells displayed higher proliferation. The proportions of both na&#x000ef;ve and Temra cells in CD4<sup>+</sup> and CD8<sup>+</sup> T cells declined, whereas those of Tcm and Tem cells elevated. In the meantime, both CD69<sup>+</sup> and CD38<sup>+</sup> T cells decreased, but the frequencies of PD-1<sup>+</sup> and CTLA-4<sup>+</sup> of CD4<sup>+</sup> and CD8<sup>+</sup> T cells showed an increasing trend. The proportions of PD-1<sup>+</sup> and CTLA-4<sup>+</sup> cells also increased in older people with long COVID symptoms at 3m post-infection.</p></sec><sec><title>Conclusions</title><p>Omicron BA.5 infection induced lower neutralizing antibodies against XBB.1 and EG.5 variant. The decrease of memory B cells, CD69<sup>+</sup> and CD38<sup>+</sup>T cells, as well as the increase of PD-1<sup>+</sup>, CTLA-4<sup>+</sup> of CD4<sup>+</sup>/CD8<sup>+</sup>T cells and double negative B cells, indicate that sustained immune responses against BA.5 infection may wane more rapidly in elderly populations.</p></sec></abstract><kwd-group><kwd>omicron BA.5</kwd><kwd>elderly</kwd><kwd>neutralizing antibody</kwd><kwd>adaptive immunity</kwd><kwd>T cell</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Key R&#x00026;D Program of China (2023YFC2308201, 2023YFC2308204); The National Pathogen Resource Center (No. NPRC-32); Research on monitoring, forecasting and early warning of unknown and emerging pathogens (2024NITFID508); Collection and Preservation of China's Critical Viral Strain Resources(ZDGWNLJS24-16).</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="1"/><equation-count count="0"/><ref-count count="56"/><page-count count="13"/><word-count count="6265"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Viral Immunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of March 2025, COVID-19 causes a pandemic with over 776 million cases and at least 7 million deaths (<xref rid="B1" ref-type="bibr">1</xref>). To date, Alpha, Beta, Gamma, Delta, and Omicron variants have been classified as a &#x02018;variant of concern&#x02019; by the World Health Organization (WHO) on the basis that they exhibit substantially altered transmissibility or immune escape, warranting close monitoring (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). After November 2021, the emergence of the Omicron (B.1.1.529) variant continued to mutate to novel subtypes, resulting in increasing immune escape and risk of reinfection and gradually evolved into the dominant strain in the world (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). In December 2022, there was an outbreak of the Omicron BA.5.2/BF.7 variant in China (<xref rid="B6" ref-type="bibr">6</xref>). From May to July 2023, the Omicron XBB variant with stronger immune evasion reached its peak of prevalence (<xref rid="B4" ref-type="bibr">4</xref>). And the EG.5 variant reached its peak of prevalence in November 2023 (<xref rid="B7" ref-type="bibr">7</xref>). Since early 2022, Omicron variants replace Delta and Alpha, with all currently circulating SARS-CoV-2 strains belonging to Omicron sub-lineages (<xref rid="B2" ref-type="bibr">2</xref>). In addition, neutralizing antibodies (Nab) may provide evidence for protection against reinfection in elderly people, although immunosenescence may not produce an adequate protective response (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). Several clinical studies show that poor antibody response is one of the risk factors for infection in the elderly, which is related to the decline of vaccine efficiency and the serious consequences of COVID-19 (<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>). Some studies show that the antibody responses of elderly participants after Omicron BA.5 infection and XBB reinfection may be affected by vaccine type and comorbidities (<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>). The continuous evolution of Omicron subvariants has led to substantial reductions in vaccine effectiveness (<xref rid="B17" ref-type="bibr">17</xref>). Given the ongoing evolution of the SARS-CoV-2 virus and the emergence of new variants, it is essential to conduct longitudinal studies on immune persistence in the elderly. This research is crucial for understanding how better to protect this vulnerable group from SARS-CoV-2 variants infection again.</p><p>The immunological memory is one of the important features of adaptive immunity. Studies of convalescent COVID-19 patients show that the level of SARS-CoV-2-specific antibodies gradually decreases over time (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>). Multiple evidence suggests that T-cell responses are associated with the reduction of symptoms of COVID-19 disease (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>). Both natural infection and vaccination can induce the population&#x02019;s immunity against COVID-19. However, previous studies find that compared with the young, the elderly have poor T-cell responses to SARS-CoV-2 caused by vaccination or infection (<xref rid="B24" ref-type="bibr">24</xref>). The patients over 65 years old have a very uncoordinated SARS-CoV-2 specific immune response compared with young patients, in which there is a reduction coordination of between CD4<sup>+</sup> and CD8<sup>+</sup>T cell responses, the loss coordination between CD4<sup>+</sup>T cells and antibody response, and changes in correlation between inflammatory cytokines and CD4<sup>+</sup>T cells, CD8<sup>+</sup>T cells, and antibody response, especially, in patients aged &#x02265;75 years old (<xref rid="B21" ref-type="bibr">21</xref>). SARS-CoV-2 infection induces specific T cell responses to various viral antigens, but the diversity of target antigen repertoire for long-lived memory T cells specific for SARS-CoV-2 may decline with age (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Several studies have reported report the immune responses and epidemiological features after Omicron BA.5 infection in the general population (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B26" ref-type="bibr">26</xref>). However, it is necessary to study the immune persistence of the elderly population and determine the characteristics of T-cell immune responses that prevent reinfection in the elderly. Thus, a longitudinal study of immunity response to SARS-CoV-2 was conducted in the elderly population of Shandong, China.</p></sec><sec id="s2"><label>2</label><title>Methods</title><sec id="s2_1"><label>2.1</label><title>Study design and participants</title><p>58 participants infected with Omicron BA.5 in December 2022 were recruited, and three follow-up visits were carried out in January, March, and June 2023 (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>) in Shandong, China. Among the 58 participants were non-hospitalized (classified as mild or moderate cases), including 9 asymptomatic individuals and 49 symptomatic individuals who recovered without requiring hospitalization. After venous blood was collected from all participants, serum, plasm, and peripheral blood mononuclear cells (PBMCs) were isolated. Before testing, PBMCs were frozen and stored in serum-free cell-freeing media (Aoqing Biotechnology Co., Ltd., China) at -80&#x000b0;C. This ethics was approved by the Ethics Committee of National Institute for Viral Disease Control and Prevention, China CDC and written informed consent was provided by the participants or their guardians before sample collection (No. IVDC2025-003).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>The flow chart of the study design. A total of 58 participants were enrolled in three visits (1m, 3m, 6m after BA.5 infection) followed up longitudinally in Shandong, China in 2023. After serum and PBMCs of participants were collected, Nab titer of WT strain, BA.5, XBB.1 and EG.5 variant and the cellular immune were detected through ICS using no peptide stimulation for all participants or peptide stimulation for the elderly.</p></caption><graphic xlink:href="fimmu-16-1596065-g001" position="float"/></fig></sec><sec id="s2_2"><label>2.2</label><title>Neutralizing antibody assays</title><p>The NAbs to SARS-CoV-2 were detected by the microneutralization tests under Vero cell using the SARS-CoV-2 protype strain and variants BA.5, EG.5.1, XBB.1.1 according to previous reports (<xref rid="B27" ref-type="bibr">27</xref>), the neutralization assays of SARS-CoV-2 were carried out under Vero cells with DMEM supplemented containing penicillin G (100 U/ml), streptomycin (100 mg/ml), 2 mM L-glutamine, and 10% heat-inactivated fetal bovine serum (FBS). All cell cultures were maintained in 5% CO2 at 37&#x000b0;C. The steps of the neutralization test were briefly described as follows: 100 &#x003bc;L of serum diluted in a 1:2 series (starting at 1:4) were added to each well of 96-well plates. Then, each well of 96-well plates was seeded with 20,000 cells in 100 &#x003bc;L of DMEM. Subsequently, 50&#x003bc;L of cell culture medium containing 100 TCID50 Wild type, BA.5, XBB.1 and EG.5 variant were added in 96-well plates under 37&#x000b0;C and the cytopathic effect (CPE) was observed after 5-day incubation.</p></sec><sec id="s2_3"><label>2.3</label><title>Evaluation of T/B cells response using flow cytometry</title><p>PBMC were washed in PBS with 1% heat-inactivated FBS (Gibco), stained with Live/Dead fix blue (Life Technologies, 1:500), and incubated for 30 minutes at 4&#x000b0;C. Cells were washed in PBS+1% FBS and incubated for 30 minutes at 37&#x000b0;C with CCR7-BV421 (Biolegend) and CD185-BV750 (Biolegend). Then, Cells were washed in PBS+1% FBS and incubated for 30 minutes to 1h at 4&#x000b0;C sheltered from light with an antibody cocktail including: CD8-BUV805 (BD), CD19-Spark NIR685 (Biolegend), CD27-BV480 (BD), CD38-APC/Fire810 (Biolegend), CD56-BUV737 (BD), CD16, CD45RA-BUV395 (BD), CD25-PE-Fire700 (Biolegend), CD127-APC-R700 (BD). Next, Cells were washed in PBS+2% FCS and permeabilized for 50 minutes in 4&#x000b0;C in 100&#x003bc;L of Transcription Factor Buffer Set (BD Biosciences). After washing in PermWash (100&#x003bc;L 1&#x000d7;perm/wash buffer), antibodies were formulated using 1&#x000d7;perm/wash buffer and incubated for 30 minutes at 4&#x000b0;C, including IL-17A-PE(Biolegend), CD4-BUV496 (BD), and CD3-BV510 (Biolegend). After washing in 1&#x000d7;perm/wash buffer and cell resuspension solution in 2% PFA, flow cytometry was performed using Cytek Aurora flow cytometry.</p><p>After PBMC of the elderly were collected in 3m and 6m of post-infection (pi), ICS was performed using stimulation of spike peptide pools of BA.5 (Qiangyao Biotechnology Co., Ltd., China). Briefly, cryopreserved PBMCs were thawed at 37&#x000b0;C and immediately washed in PBS, the suspension was performed using CTL medium containing nuclease (Benzonase<sup>&#x000ae;</sup>, 1:5000), and the cells were recovered at 37&#x000b0;C for 3 to 4h and counted. Cells were cultured for 6 hours in the 5 &#x003bc;L PMA+Ionomycin (Dakewe), DMSO, and spike peptide pools of the BA.5 variants (5&#x003bc;g/mL) in 96-wells U-bottom plates at 1x10<sup>6</sup> PBMC per well, respectively. And add eBioscience<sup>TM</sup> Brefeldin A Solution per well blocker. Stimulation with an equimolar amount of DMSO was performed as a negative control, and PMA+Ionomycin was included as a positive control. Then, dyeing of PBMC treatment as described above. Extracellular antibody cocktail including CD19-Spark NIR685 (Biolegend), CD25-PE-Fire700 (Biolegend), CD366-PE/Dazzle594 (Biolegend), CD152-PE (Biolegend), CD45RA-BUV395 (BD), CD20-BV570 (Biolegend), CD279-BV785 (Biolegend), CD38-APC/Fire810 (Biolegend), CD27-BV480 (BD), IgD-PE/Cyanine5 (Biolegend), CD8-BUV805 (BD), CD56-BUV737 (BD), CD69-BUV661 (BD). Intracellular antibody cocktail including Perforin-FITC (BD), CD4-BUV496 (BD), Granzyme B-eFluo 450 (Thermo) and CD3-BV510 (Biolegend). After washing in 1&#x000d7;perm/wash buffer and cell resuspension solution in 2% PFA, flow cytometry was performed using Cytek Aurora flow cytometry.</p></sec><sec id="s2_4"><label>2.4</label><title>Statistical analysis</title><p>The demographic characteristics of the participants were presented as the median (IQR) for continuous variables and the absolute values and percentages for categorical variables. Nab were presented as the geometric mean titers (GMTs) with 95% confidence intervals (CIs). The difference between groups was examined by a Wilcoxon matched-pairs signed rank test or Mann-Whitney U-test as appropriate. A two-sided P-value &#x0003c; 0.05 was considered statistically significant. The statistical analysis was conducted using GraphPad Prism 9.0 (GraphPad Software, San Diego, USA) and IBM SPSS Statistics 26 (SPSS Inc., Chicago, USA).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>The epidemiological characteristics of participants</title><p>A total of 58 participants were enrolled in the study, their median age was 60.5 years old (age range: 34&#x02013;86 years old) (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>), and the male to female ratio was 1:1.30. Among them, 53.44% of the population was over 60 years old, with a male to female ratio of 1:1.38. All individuals received SARS-CoV-2 vaccine. 96.55% (56/58) of people received a booster dose of inactivated vaccine. Among them, 89.66% (52/58) of people received at least one booster of CoronaVac or BBIBP-CorV vaccine. The first dose of inactivated vaccines was primarily administered in 2021(96.55%, 56/58), and the second dose was also mainly administered in 2021(93.10%, 54/58), for the third vaccination, 55.36% (31/56) individuals received it in 2021 and 44.64% (25/56) in 2022. Additionally, 39.66% (n=23) of the participants suffered from underlying diseases, of which hypertension, diabetes, or coronary heart disease were the most common comorbidities. Among the participants, 49 were symptomatic and 9 were asymptomatic according to a questionnaire survey. The common symptoms were fever (87.76%), cough (75.55%), fatigue (73.47%), expectoration (71.43%), and sore throat (65.31%).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>The epidemiological characteristics of participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Participants (n = 58)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;(median, IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">60.5 (48-70)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Sex (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">25 (43.10)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">33 (58.90)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Comorbidities (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="top" align="left" rowspan="1" colspan="1">23 (39.66)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="top" align="left" rowspan="1" colspan="1">35 (60.34)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Omicron BA.5 infection (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">9 (15.52)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;symptomatic</td><td valign="top" align="left" rowspan="1" colspan="1">49 (84.48)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Symptomatic infection(n=49)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fever</td><td valign="top" align="left" rowspan="1" colspan="1">43 (87.76)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Cough</td><td valign="top" align="left" rowspan="1" colspan="1">38 (75.55)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fatigue</td><td valign="top" align="left" rowspan="1" colspan="1">36 (73.47)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Expectoration</td><td valign="top" align="left" rowspan="1" colspan="1">35 (71.43)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Sore throat</td><td valign="top" align="left" rowspan="1" colspan="1">32 (65.31)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pain in the lower back and limbs</td><td valign="top" align="left" rowspan="1" colspan="1">30 (61.22)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Headache</td><td valign="top" align="left" rowspan="1" colspan="1">26 (53.06)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Dizzy</td><td valign="top" align="left" rowspan="1" colspan="1">22 (44.90)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chest distress</td><td valign="top" align="left" rowspan="1" colspan="1">21 (42.86)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Diarrhea</td><td valign="top" align="left" rowspan="1" colspan="1">12 (24.49)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Nausea or vomiting</td><td valign="top" align="left" rowspan="1" colspan="1">9 (18.37)</td></tr><tr><th valign="top" colspan="2" align="left" rowspan="1">Booster vaccination (n=52)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CoronaVac</td><td valign="top" align="left" rowspan="1" colspan="1">22 (42.31)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;BBIBP&#x02010;CorV</td><td valign="top" align="left" rowspan="1" colspan="1">30 (57.69)</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><label>3.2</label><title>Changes of Nab titers after 6 months of BA.5 infection</title><p>To evaluate the changes in Nab titers in individuals infected with the Omicron BA.5 variant, a follow-up study was conducted involving 58 participants. Serum samples were collected at three time points: the 1<sup>st</sup> month, the 3<sup>rd</sup> month, and the 6<sup>th</sup> month pi. The Nab titers were tested against the WT, BA.5, XBB.1, and EG.5 strains, respectively. The Nab titers against the WT strain were the highest at each time point, followed by BA.5, XBB.1, and EG.5 variants (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>). GMTs of WT strain was 238.76 (95% CI, 167.11-341.15), 278.49 (95% CI, 221.8-349.67), and 208.29 (95% CI, 153.81-282.09) in 1m, 3m and 6m pi, and the GMTs of BA.5 variant were 194.41 (95% CI, 135.52-278.89), 212.82 (95% CI, 157.67-287.24), and 130.26 (95% CI, 100.16-169.41). The XBB.1 variant was 33.62 (95% CI, 26.40-42.85), 29.54 (95% CI, 22.99-37.97), and 30.16 (95% CI, 24.1-37.75). And there was a lower level of the Nab titers against EG.5 variant. The antibody titers of EG.5 variant at the three time points were 9.48 (95%CI, 7.53-11.93), 10.18 (95%CI, 8.42-12.31), and 11.98 (95%CI, 9.91-14.50) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure&#x000a0;1</bold>
</xref>), respectively. The titers of XBB.1 were remarkably lower than those of BA.5 by 5.78-fold, 7.20-fold, and 4.32-fold in 1m, 3m, and 6m pi, respectively. Whether the elderly or the middle-aged, Nab titers against both WT and BA. 5 strains remained at a high level at each time point, and those of XBB.1 and EG.5 variants were at a relatively low level, especially the EG.5 variant (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure&#x000a0;2</bold>
</xref>). But the Nab titers of the WT and BA.5 strains were lower in older people than in the middle-aged (<italic>P</italic>&#x0003e;0.05) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure&#x000a0;2</bold>
</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>NAb titers of WT and Omicron BA.5, XBB.1, EG.5 variants in 1m, 3m and 6m pi, respectively. NAb titers changes in the 58 participants in 1m <bold>(A)</bold>, 3m <bold>(B)</bold>, and 6m <bold>(C)</bold> after BA.5 infection. The bar indicates geometric mean titers (GMT) with a 95% confidence interval (CI). A Wilcoxon matched-pairs signed rank test was performed in this analysis and <italic>P</italic> &#x0003c; 0.05 was considered statistically significant. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001, ****<italic>P</italic> &#x0003c; 0.0001. ns represents no statistical significance.</p></caption><graphic xlink:href="fimmu-16-1596065-g002" position="float"/></fig><p>The effects of booster vaccination, gender, symptoms, and comorbidities on the level of Nab of SARS-CoV-2 variants were then analyzed. Nab titers against the WT strain, BA.5, XBB.1 and EG.5 variants were not significantly different between the CoronaVac and BBIBP-CorV (<italic>P</italic>&#x0003e;0.05) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3A</bold>
</xref>). Our results showed that individuals who experienced Omicron infection within &#x0003c;12 months after booster vaccination exhibited higher Nab levels against WT, BA.5 and XBB.1 variants at 1 month post-infection (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3B</bold>
</xref>). We further analyzed the impact of comorbidities on Nab titers in elderly individuals. The results showed that the Nab levels were lower in patients with comorbidities compared to those without. Notably, the antibody titers were lower in patients with cardiovascular diseases than in those with diabetes, although this difference was not statistically significant. Additionally, the Nab levels against BA.5 and XBB.1 variants in patients with cardiovascular disease were significantly lower than those patients without comorbidities (<italic>P</italic> &#x0003c; 0.05) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3C</bold>
</xref>). When antibody levels were analyzed in individuals with underlying diseases, the Nab titers of WT, BA.5, XBB.1, and EG.5 strains in the normal population were significantly higher than those in individuals with comorbidities (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3C</bold>
</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>The impact of vaccination and comorbidities on Nab levels of participants. <bold>(A)</bold> Comparison of Nab titers against WT strain, BA.5, XBB.1 and EG.5 variants in patients infected with SARS-CoV-2 after receiving BBIBP-CorV and CoronaVac vaccines. <bold>(B)</bold> Comparison of Nab levels against the WT strain, BA.5, XBB.1 and EG.5 variants between individuals with SARS-CoV-2 inactivated vaccine booster-infection intervals of &#x0003c;12 months and &#x02265;12 months. <bold>(C)</bold> Comparison of Nab levels against the WT strain, BA.5, XBB.1, and EG.5 variants between elderly individuals with comorbidity and those without comorbidity. The bar indicates the GMT with a 95% CI. A Mann-Whitney test was performed in this analysis and P &#x0003c; 0.05 was considered statistically significant. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001, ****<italic>P</italic> &#x0003c; 0.0001. ns represents no statistical significance.</p></caption><graphic xlink:href="fimmu-16-1596065-g003" position="float"/></fig></sec><sec id="s3_3"><label>3.3</label><title>The characteristic of the memory B cells, Tfh cells, and Th17 cells in the elderly</title><p>To understand the dynamic changes of the immune cells of the population after Omicron BA.5 infection, memory B cells, CD4<sup>+</sup>T cells, CD8<sup>+</sup>T cells, and CD4<sup>+</sup>T cell subset were detected at the above three time points. The results showed that the total number of total CD4<sup>+</sup>T cells remained stable at 1m, 3m and 6m pi and CD8<sup>+</sup>T cells showed a significant decreasing trend over time (<xref rid="f4" ref-type="fig">
<bold>Figures&#x000a0;4A, B</bold>
</xref>). The number of Th1 cells decreased over time from 1m pi to 3m pi and then stabilized until 6m pi, whereas Th2 cells showed the opposite trend (<xref rid="f4" ref-type="fig">
<bold>Figures&#x000a0;4C, D</bold>
</xref>). The number of CD4<sup>+</sup>Treg cells decreased continuously over time whether in older people or the middle-aged population (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4E</bold>
</xref>). However, the number of memory B cells in the elderly population decreased with the prolongation of post-infection time. Still, the number of memory B cells (MBC) in the middle-aged population continued to grow from 1m to 3m pi and remained relatively stable from 3m to 6m pi (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4F</bold>
</xref>). Our results also showed that the number of Tfh cells and Th17 cells continuously increased in a middle-aged population. However, the number of Tfh cells and Th17 cells showed a characteristic of first increasing from 1m to 3m pi and then decreasing from 3m to 6m pi in older people (<xref rid="f4" ref-type="fig">
<bold>Figures&#x000a0;4G, H</bold>
</xref>).</p><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Subset changes of T cells, B cells and NK cells after Omicron BA.5 infection. The number of T cells, B cells and NK cells without peptide stimulation in middle-age in 34&#x02013;59 years old (pink), the elderly over 60 years old (green), the elderly over 70 years old (blue) in 1m, 3m, and 6m pi, respectively. <bold>(A, B)</bold> Kinetics of CD4<sup>+</sup> and CD8<sup>+</sup>T cells responses in three age groups. <bold>(C, D)</bold> Kinetics of Th1 and Th2 cells in three age groups. <bold>(E)</bold> Kinetics of CD4<sup>+</sup>Treg cells in three age groups. <bold>(F)</bold> Kinetics of memory B cells responses in three age groups. <bold>(G)</bold> Kinetics of Tfh cells responses in three age groups. <bold>(H)</bold> Kinetics of Th17 cells responses in three age groups. <bold>(I)</bold> Kinetics of NK cells responses in three age groups. <bold>(J, K)</bold> Kinetics of mature NK and immature NK cells responses in three age groups, respectively. <bold>(L)</bold> Kinetics of immature NKT cells responses in three age groups.</p></caption><graphic xlink:href="fimmu-16-1596065-g004" position="float"/></fig><p>NK cells and NKT cells, the main groups of immune cells involved in innate immunity, were also analyzed in this study. The proportion of NK cells decreased rapidly from 1m pi to 6m pi, with the fastest decline in people over 70 years of age (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4I</bold>
</xref>). The proportion of mature NK cells in the middle-aged population increased from 1m pi to 3m pi and remained stable from 3m pi to 6m pi. Mature NK cells in the older population showed a similar trend from 1m to 3m pi, but it decreased from 3m to 6m pi. Our results also showed that the proportion of mature NK cells was higher than in the middle-aged in the older people at each time point (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4J</bold>
</xref>). However, immature NK cells exhibited a completely opposite trend (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4K</bold>
</xref>). The proportion of NKT cells in all age groups showed a decreasing trend (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4L</bold>
</xref>).</p></sec><sec id="s3_4"><label>3.4</label><title>SARS-CoV-2-specific cellular immunity of the elderly after infection</title><sec id="s3_4_1"><label>3.4.1</label><title>Activation of CD4<sup>+</sup>/CD8<sup>+</sup>T cells decreased in older people</title><p>To characterize the specific cellular immune effects and immune memory response in older people, PBMCs from the elderly at 3m pi and 6m pi were stimulated with the peptide pool of S protein of BA.5 variants. After stimulation, both CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells showed a decreasing trend from 3m to 6m pi (<xref rid="f5" ref-type="fig">
<bold>Figures&#x000a0;5A, B</bold>
</xref>). Then, T-cell activation was identified through detection of CD38 and CD69 markers. The result found that the proportion of both CD38<sup>+</sup> T cells and CD69<sup>+</sup> T cells decreased from 3m to 6m pi (<xref rid="f5" ref-type="fig">
<bold>Figures&#x000a0;5C, D</bold>
</xref>). To investigate the memory phenotypes of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, the proportion of the na&#x000ef;ve (CD45RA<sup>+</sup>CCR7<sup>+</sup>), central memory (Tcm, CD45RA<sup>&#x02212;</sup>CCR7<sup>+</sup>), effector memory (Tem, CD45RA<sup>&#x02212;</sup>CCR7<sup>&#x02212;</sup>), and late effector (Temra, CD45RA<sup>+</sup>CCR7<sup>&#x02212;</sup>) subsets were determined by detection of both CD45RA and CCR7. The results showed that the specific Tcm, Tem, na&#x000ef;ve, and Temra cells of CD4<sup>+</sup> T cells in the elderly accounted for 47.21%, 13.61%, 32.25%, and 6.93% in 3m pi, respectively (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5E</bold>
</xref>). Compared with Tcm and Tem cells at 3m pi, both Tcm and Tem cells of the elderly increased significantly at 6m pi (57.94%, 26.20%), whereas both na&#x000ef;ve and Temra cells decreased at 6m pi (14.31%, 1.55%) (<italic>P</italic>&#x0003c;0.05) (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5E</bold>
</xref>).</p><fig position="float" id="f5"><label>Figure&#x000a0;5</label><caption><p>SARS-CoV-2-specific T cell responses in elderly individuals at 3m and 6m pi. After SARS-CoV-2 spike peptide stimulation, <bold>(A)</bold> specific CD4<sup>+</sup> T cells and <bold>(B)</bold> specific CD8<sup>+</sup> T cells in elderly individuals at 3m and 6&#x000a0;m pi. <bold>(C)</bold> CD38<sup>+</sup> T cells and <bold>(D)</bold> CD69<sup>+</sup> T cells levels in elderly individuals at 3m and 6&#x000a0;m pi. <bold>(E)</bold> specific CD4<sup>+</sup> T cell and <bold>(F)</bold> CD8<sup>+</sup> T cell memory phenotypes: na&#x000ef;ve, central memory T cells, effector memory T cells, terminally differentiated effector T cells. The bar chart shows dynamic changes from 3m to 6m. The pie chart shows the proportion of four memory T cell phenotypes at 3m and 6m. A Mann-Whitney test was performed in this analysis and P &#x0003c; 0.05 was considered statistically significant. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001, ****<italic>P</italic> &#x0003c; 0.0001. ns represents no statistical significance.</p></caption><graphic xlink:href="fimmu-16-1596065-g005" position="float"/></fig><p>Similar to the results above, for CD8<italic>
<sup>+</sup>
</italic> T cells, Tcm cells increased from 5.53% to 32.02%, and Tem cells increased from 9.42% to 15.49% from 3m to 6m pi in older people (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5F</bold>
</xref>). However, the Temra cells decreased from 37.85% to 12.49%, and na&#x000ef;ve cells decreased from 47.20% to 39.99% from 3m to 6m pi, respectively (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5F</bold>
</xref>).</p></sec><sec id="s3_4_2"><label>3.4.2</label><title>MBC, unswitched/switched MBC decreased and DNBC increased in elderly</title><p>The function of NK cells and B cells was then assessed following stimulation with the peptide pool. The four subsets of B cells, namely na&#x000ef;ve/transitional B cells (CD27<sup>-</sup>IgD<sup>+</sup>), unswitched memory B cells (unswitched MBC, CD27<sup>+</sup>IgD<sup>+</sup>), switched memory B cells (switched MBC, CD27<sup>+</sup>IgD<sup>-</sup>), and double negative B cells (CD27<sup>-</sup>IgD<sup>-</sup>), were evaluated according to the different expression levels of CD19, CD27, and IgD. The results showed that the B cells (CD19<sup>+</sup>) increased slightly from 3m to 6m pi (<italic>P</italic>&#x0003e;0.05) (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6A</bold>
</xref>). Comparing the B cell subsets of convalescents at 3m and 6m pi, it was found that na&#x000ef;ve B cells, unswitched MBC, and switched MBC were significantly lower in 6m pi than in 3m pi, but double negative B cells (DNBC) were considerably higher than that in 3m pi (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6B</bold>
</xref>). The na&#x000ef;ve B cells made up the majority of B cells in 3m pi, whereas DNBC made up the majority of B cells in 6m pi. Furthermore, the frequency of unswitched MBC was lower than switched MBC in both 3m pi and 6m pi (<xref rid="f6" ref-type="fig">
<bold>Figures&#x000a0;6C, D</bold>
</xref>). Our results also showed that the Perforin<sup>+</sup>, Granzyme<sup>+</sup> of NK cells and CD8<sup>+</sup>T cells also decreased slightly after stimulation (<xref rid="f6" ref-type="fig">
<bold>Figures&#x000a0;6E, F</bold>
</xref>).</p><fig position="float" id="f6"><label>Figure&#x000a0;6</label><caption><p>The frequencies of SARS-CoV-2-specific memory B cells, NK cells and CTL cells in the elderly at 3m and 6m pi. <bold>(A)</bold> The changes in B cells at 3m, 6m pi in elderly convalescent patients. <bold>(B)</bold> Classification of B cell subtypes in elderly convalescent patients at 3m and 6m pi. <bold>(C)</bold> Proportional distribution of B cell subtypes at 3m pi in elderly convalescent patients. <bold>(D)</bold> Proportional distribution of B cell subtypes at 6m pi in elderly convalescent patients. <bold>(E)</bold> The changes of mature NK cells (Perforin<sup>+</sup> GranzymB<sup>+</sup>, CD56<sup>+</sup>) at 3m, 6m pi in elderly convalescent patients. <bold>(F)</bold> The changes of CTL cells (Perforin+ GranzymB<sup>+</sup>, CD8<sup>+</sup>) at 3m, 6m pi in elderly convalescent patients. A Mann-Whitney test was performed in this analysis and P &#x0003c; 0.05 was considered statistically significant. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001, ****<italic>P</italic> &#x0003c; 0.0001. ns represents no statistical significance.</p></caption><graphic xlink:href="fimmu-16-1596065-g006" position="float"/></fig></sec><sec id="s3_4_3"><label>3.4.3</label><title>PD-1<sup>+</sup>/CTLA-4<sup>+</sup> CD4<sup>+</sup>/CD8<sup>+</sup> T-cell increased in older people</title><p>Immune regulation determines not only the occurrence of an immune response caused by a viral infection but also determines the strength of the immune response. Regulatory T cells (Tregs) are the leading immunosuppressive cell group that maintains the immune balance of the body. Our results showed that CD4<sup>+</sup> Tregs cells increased significantly from 3m to 6m pi, while CD8<sup>+</sup> Tregs cells decreased significantly in 3m to 6m pi in older people (<italic>P</italic>&#x0003c;0.05) (<xref rid="f7" ref-type="fig">
<bold>Figure&#x000a0;7A</bold>
</xref>). Immune checkpoint (ICP) is another type of immunosuppressive molecule that can regulate immune responses and prevent normal tissue damage and destruction. The common ICP molecules include programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and mucin-domain containing 3 (Tim-3) (<xref rid="B28" ref-type="bibr">28</xref>). To understand the effect of ICP molecules in the elderly after BA.5 infection, PD-1<sup>+</sup> (CD279), CTLA-4<sup>+</sup> (CD152), and Tim-3<sup>+</sup> (CD366) of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were detected in this study. The results showed that PD-1<sup>+</sup> of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were significantly increased from 3m to 6m pi (<xref rid="f7" ref-type="fig">
<bold>Figure&#x000a0;7B</bold>
</xref>). CTLA-4<sup>+</sup> (CD152) cells of CD4<sup>+</sup> and CD8<sup>+</sup> T-cell also increased from 3m to 6m pi (<italic>P</italic>&#x0003e;0.05) (<xref rid="f7" ref-type="fig">
<bold>Figure&#x000a0;7C</bold>
</xref>). Additionally, Tim-3<sup>+</sup> cells of CD4<sup>+</sup> T cells slightly increased, while Tim-3<sup>+</sup> cells of CD8<sup>+</sup> T-cell significantly decreased from 3m to 6m pi (<xref rid="f7" ref-type="fig">
<bold>Figure&#x000a0;7D</bold>
</xref>).</p><fig position="float" id="f7"><label>Figure&#x000a0;7</label><caption><p>The changes of Treg cells and immune checkpoint molecules in the elderly. After SARS-CoV-2 spike peptide stimulation, <bold>(A)</bold> The changes of CD4<sup>+</sup> Treg and CD8<sup>+</sup> Treg cells at 3m, 6m pi in elderly convalescent patients. <bold>(B)</bold> The changes of CD4<sup>+</sup>PD-1<sup>+</sup> and CD8<sup>+</sup>PD-1<sup>+</sup> cells at 3m, 6m pi in elderly convalescent patients. <bold>(C)</bold> The changes of CD4<sup>+</sup>TIM-3<sup>+</sup> and CD8<sup>+</sup>TIM-3<sup>+</sup> cells at 3m, 6m pi in elderly convalescent patients. <bold>(D)</bold> The changes of CD4<sup>+</sup>CTLA-4<sup>+</sup> and CD8<sup>+</sup>CTLA-4<sup>+</sup> cells at 3m, 6m pi in elderly convalescent patients. A Mann-Whitney test was performed in this analysis and P &#x0003c; 0.05 was considered statistically significant. *<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01, ***<italic>P</italic> &#x0003c; 0.001, ****<italic>P</italic> &#x0003c; 0.0001. ns represents no statistical significance.</p></caption><graphic xlink:href="fimmu-16-1596065-g007" position="float"/></fig><p>In a 3m pi follow up study of elderly individuals with long COVID, six participants reported having at least one persistent symptom that lasted for &#x02265;2 months. Further analysis revealed that the PD-1, CTLA-4, and Tim-3, were elevated in elderly subjects with long COVID symptoms compared to those without, even if there is no statistical difference for the majority. Although the majority of these differences did not reach statistical significance (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure&#x000a0;3</bold>
</xref>).</p></sec></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>Older people are highly vulnerable to SARS-CoV-2 and its variants, mainly due to their poor antibody response (<xref rid="B29" ref-type="bibr">29</xref>). Therefore, it is crucial to determine whether the immune response to SARS-CoV-2 and its variants is preserved after Omicron BA.5 infection. To our knowledge, this study is the first to describe the dynamic changes in specific humoral and cellular immunity to Omicron BA.5 in elderly individuals.</p><p>Our study found that the Nab titers to WT and BA.5 were obviously higher than those of XBB.1 and EG.5 from 1m to 6m after BA.5 infection. The results indicated that the individuals infected with the SARS-CoV-2 variant had a stimulated immune memory response to the WT strain and showed higher immune protection against the BA.5 variant, but there was a poor cross-reaction against XBB.1 and EG.5 variant, which is consistent with the previously reported studies (<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). This likely reflects immune evasion driven by key mutations in the spike receptor-binding domain (RBD). Specifically, F456L and F486P substitutions in XBB.1 variant alter antibody-binding interfaces through structural remodeling (<xref rid="B34" ref-type="bibr">34</xref>), while the F456L/Q52H mutations in EG.5 enhance ACE2 binding and simultaneously evade common neutralizing antibodies (<xref rid="B35" ref-type="bibr">35</xref>). These findings were consistent with structural evidence indicating that F456L mutation alone reduces antibody neutralization potency by &#x0003e;20-fold (<xref rid="B34" ref-type="bibr">34</xref>). Prior to the emergence of Omicron variants, the effectiveness of CoronaVac booster vaccination in preventing symptomatic COVID-19 among adults was 78.8% (<xref rid="B36" ref-type="bibr">36</xref>), Vaccine-induced neutralizing antibody titers against the Omicron variant were 16.5-fold lower compared to those against the prototype strain (<xref rid="B37" ref-type="bibr">37</xref>). Our findings also showed that the Nab titer of the WT strain at the time of booster vaccination that &#x0003c; 12&#x000a0;m was significantly higher than that of &#x02265;12 m. Similar to early results (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B38" ref-type="bibr">38</xref>), the Nab titer of the WT strain and the Omicron BA.5 strain was weaker in older people. This may suggest that the elderly are more susceptible to infection with new variant strains. We also found that fever, cough, and fatigue were the most obvious symptoms among the older population following Omicron BA.5 infection.</p><p>Similar to our research findings in the middle-aged population, after symptomatic SARS-CoV-2 infection, the frequency of MBC peaks between 4 and 5 months (<xref rid="B20" ref-type="bibr">20</xref>). However, MBCs frequencies decreased from 3m to 6m pi in the elderly individuals. MBC are a subtype of B cells that form in germinal center after an initial infection and play an important role in producing an accelerated and stronger antibody-mediated immune response (also known as secondary immune response) in the event of a subsequent infection. In the human immune system, the number of MBC is generally higher than that of na&#x000ef;ve B cells in the peripheral blood, especially in the elderly population (<xref rid="B39" ref-type="bibr">39</xref>). However, in our study, the number of MBC was lower than that of na&#x000ef;ve B cells in 3m pi. The decrease in MBC may be due to their transformation into plasma cells that produce a large amount of antibodies. Our results also showed that both unswitched MBC and switched MBC decreased to a lower level, and Na&#x000ef;ve B cells decreased from 55.85% to 37.97%. However, the double negative B cells (DNBC), as late-stages memory cells, increased from 15.59% in 3m pi to 58.37% in 6m pi. DNBC can secrete inflammatory mediators such as TNF-&#x003b1;, IL-6, and IL-8 (<xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>), which may be involved in the persistent inflammatory response in the elderly population. From our results, it appears that the expansion of DNBCs is not related to antibody production, but may be related to the persistent increase in cytokines. This expansion of such cells can also be shown in critically ill patients with COVID-19 exhibiting characteristics of lupus-like autoimmune disease (<xref rid="B42" ref-type="bibr">42</xref>).</p><p>MBC have a long lifespan and remain in a dormant state until they reencounter antigens. As exposed to exogenous antigens again, Tfh cells immediately reactivate MBC, which differentiate into plasma cells capable of secreting antibodies. Similar to the trend of unswitched MBC and switched MBC, the number of Tfh cells in the elderly population showed a peak in the third month after infection and a decrease in the sixth month after infection. This result demonstrated the synergistic effect between Tfh cells and MBC after SARS-CoV-2 infection. The number of Th17 and Tfh cells in middle-aged people continued to increase with prolonged infection time. Th17 cells are associated with protective immune responses in specific viral infection models (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). However, in other cases, they have been shown to promote the pathogenesis of viral diseases (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B46" ref-type="bibr">46</xref>). From our research results, the Th17 cell continued to increase after infection in middle-aged people, suggesting that it does not promote the prognosis of patients with COVID-19 infection. The functional relevance of the Th17 response to COVID-19 requires further investigation.</p><p>Our results showed that, in elderly individuals, the proportions of na&#x000ef;ve and Temra cells in CD4<sup>+</sup>/CD8<sup>+</sup>T cells decline, whereas those of Tcm and Tem cells rise. Notably, the proportion of na&#x000ef;ve cells in CD4<sup>+</sup>T cells is significantly lower than that of Tcm cells. After T-cell division and differentiation, memory T cells and effector T cells are formed, respectively. Memory T cells can exist in the human body for months or even decades, preventing the body from being invaded again by the relevant pathogens. The validity period of some memory T cells is very short, such as influenza, hepatitis B, etc., but some are lifetime, such as smallpox (<xref rid="B47" ref-type="bibr">47</xref>&#x02013;<xref rid="B49" ref-type="bibr">49</xref>). Memory T cells are typically divided into three main groups: Tcm, Tem, and Temra cells. This study showed that Tcm of CD4<sup>+</sup> T cells from older people showed a significantly higher proliferation frequency from 47.21% to 57.94% over time. Tcm cells of CD8<sup>+</sup>T cells increased rapidly from 5.53% 3m pi to 32.03% 6m pi. This may be due to the rapid transformation of na&#x000ef;ve T cells, prompting the body to respond quickly. Temra cells decreased from 6.93% to 1.55% for CD4<sup>+</sup>T cells, and Temra cells of CD8<sup>+</sup>T cells rapidly reduced from 37.85% to 12.49%. The results indicate that at the early stage (3m pi), Temra cells may play some roles in the early inflammation of COVID-19 infection. Our results still showed that the Tem cells of CD4<sup>+</sup> cells increased from 13.61% to 26.20%, and the Tem cells of CD8<sup>+</sup> cells also increased from 9.42% to 15.49%, respectively. This suggests that the Tcm cells may be one of important immune protection in the elderly population. A decreased proportion of na&#x000ef;ve CD4<sup>+</sup>T cells indicates that the immune response to new antigens in the elderly population is limited. It is difficult to establish long-term and adequate immune protection, and they may be more prone to reinfection.</p><p>Na&#x000ef;ve CD4<sup>+</sup> T cells differentiate into several effector cell subsets based on their function and the cytokines they release. The major subsets are Th1, Th2, Th17, Treg and Tfh cells (<xref rid="B50" ref-type="bibr">50</xref>). Th1 cells are essential for the host&#x02019;s defense toward intracellular pathogens (<xref rid="B51" ref-type="bibr">51</xref>), while Th2 cells mediate the activation and maintenance of the antibody-mediated immune response against extracellular parasites, bacteria, allergens, and toxins (<xref rid="B52" ref-type="bibr">52</xref>). Similar to typical research findings, our study showed that both the elderly and middle-aged populations exhibited opposite trends in Th1 and Th2 cell responses over time. Within 6 months after COVID-19 infection, NK cells and NKT cells decreased with the extension of post-infection time in both the elderly and middle-aged populations. The results suggest that the antiviral response of the body infected with COVID-19 gradually returns to normal. Our results also showed that the number of mature NK cells in the elderly population was slightly lower than that in the middle-aged population.</p><p>Tregs are key immunosuppressive cells that migrate to areas of inflammation and help suppress the inflammatory response (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). We found that the number of CD4<sup>+</sup>Treg cells increased with time after infection, while the number of CD8<sup>+</sup>Treg cells showed the opposite trend. PD-1, Tim-3, and CTLA-4 of ICP molecules are associated with T cell depletion (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). At 6 months after infection, the number of cells expressing PD-1<sup>+</sup>, CTLA-4<sup>+</sup> in CD4<sup>+</sup> and CD8<sup>+</sup> cells were higher than that at 3 months after infection; A previous study demonstrates that PD-1 expressing SARS-CoV-2 specific CD4<sup>+</sup> T cells were exhausted (<xref rid="B46" ref-type="bibr">46</xref>). In our study, PD-1 showed an increasing trend in the elderly after infection. Thus PD-1 expressed on effector SARS-CoV-2 specific T cells may gradually act as an exhaustion marker in the long-term recovery phase over time. CTLA-4 also increased during recovery, consistent with other studies (<xref rid="B56" ref-type="bibr">56</xref>). This further suggests that these older people do not maintain persistent immune function after infection. Divergent Treg dynamics and rising immune exhaustion markers: unveiling the older people&#x02019;s post-infection immune vulnerability.</p><p>This study has several limitations. Firstly, the small sample size of elderly participants will limit the scalability of our results. Secondly, the lack of a control cohort for young people makes it impossible to exclude age-specific immune features.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusion</title><p>There are few studies on adaptive immune cohorts of Omicron variants in the elderly after the COVID-19 pandemic. Here we find that the Nab titers showed higher immune protection against the WT strains and BA.5 variant after BA.5 infection, but poor cross-reaction against XBB.1 and EG.5, which means that these populations are more likely to be infected with either XBB.1 or EG.5 again. The decrease of the MBC, unswitched/switched MBC and CD69<sup>+</sup>/CD38<sup>+</sup>T cells, the differences in Tfh and Th17 cell changes between the elderly population and the middle-aged population, as well as the increase of CD4<sup>+</sup>/CD8<sup>+</sup>PD-1<sup>+</sup> T cells, CTLA-4<sup>+</sup>CD4<sup>+</sup>/CD8<sup>+</sup>T cells and DNBC, suggest that the elderly exhibit a reduced persistent immune response to BA.5 infection. In addition, elderly individuals with comorbidities have an increased risk of developing serious illnesses when reinfected with XBB.1 and EG.5 variants. Vaccination of the elderly population against newly emerging variants is one of the key strategies to reduce the risk of reinfection for this vulnerable group.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all participants, including study volunteers enrolled in the study.</p></ack><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>QL: Validation, Methodology, Investigation, Software, Visualization, Writing &#x02013; original draft. QS: Visualization, Writing &#x02013; original draft, Data curation, Methodology, Software. YL: Data curation, Writing &#x02013; original draft, Resources, Investigation, Software. KZ: Writing &#x02013; original draft, Validation, Methodology. TL: Writing &#x02013; original draft, Data curation, Investigation. JMH: Methodology, Writing &#x02013; original draft, Software. GM: Writing &#x02013; original draft, Project administration, Data curation. HD: Supervision, Validation, Writing &#x02013; original draft. ZX: Writing &#x02013; original draft, Methodology. ML: Writing &#x02013; original draft, Methodology. JS: Writing &#x02013; original draft. CG: Writing &#x02013; original draft, Methodology. DX: Methodology, Writing &#x02013; original draft. GX: Methodology, Writing &#x02013; original draft. WT: Methodology, Writing &#x02013; original draft. YQ: Writing &#x02013; original draft, Methodology. ZK: Supervision, Investigation, Conceptualization, Resources, Writing &#x02013; review &#x00026; editing. ZD: Writing &#x02013; review &#x00026; editing, Formal Analysis, Conceptualization, Methodology, Supervision, Investigation. JH: Conceptualization, Writing &#x02013; original draft, Methodology, Supervision, Project administration, Resources, Writing &#x02013; review &#x00026; editing, Formal Analysis.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s13"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1596065/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1596065/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="DataSheet1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <article-title>WHO Coronavirus (COVID-19) Dashboard with Vaccination Data 2023</article-title> . Available online at: <uri xlink:href="https://data.who.int/dashboards/covid19">https://data.who.int/dashboards/covid19</uri> (Accessed <date-in-citation content-type="access-date">May 8, 2025</date-in-citation>).</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carabelli</surname><given-names>AM</given-names></name><name><surname>Peacock</surname><given-names>TP</given-names></name><name><surname>Thorne</surname><given-names>LG</given-names></name><name><surname>Harvey</surname><given-names>WT</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Consortium</surname><given-names>C-GU</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 variant biology: immune escape, transmission and fitness</article-title>. <source>Nat Rev Microbiol</source>. (<year>2023</year>) <volume>21</volume>:<page-range>162&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41579-022-00841-7</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortega</surname><given-names>MA</given-names></name><name><surname>Garcia-Montero</surname><given-names>C</given-names></name><name><surname>Fraile-Martinez</surname><given-names>O</given-names></name><name><surname>Colet</surname><given-names>P</given-names></name><name><surname>Baizhaxynova</surname><given-names>A</given-names></name><name><surname>Mukhtarova</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Recapping the features of SARS-coV-2 and its main variants: status and future paths</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>(<issue>6</issue>):<page-range>995</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jpm12060995</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ao</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name></person-group>. <article-title>The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants</article-title>. <source>MedComm (2020)</source>. (<year>2023</year>) <volume>4</volume>:<elocation-id>e239</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/mco2.239</pub-id>
<pub-id pub-id-type="pmid">36938325</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>H</given-names></name><name><surname>Tessier</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Blomquist</surname><given-names>P</given-names></name><name><surname>Simons</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England</article-title>. <source>Epidemiol Infect</source>. (<year>2023</year>) <volume>151</volume>:<elocation-id>e58</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1017/S0950268823000420</pub-id>
<pub-id pub-id-type="pmid">36938806</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis</article-title>. <source>Lancet</source>. (<year>2023</year>) <volume>401</volume>:<page-range>664&#x02013;72</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(23)00129-0</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Chinese Center for Disease Control and Prevention</collab></person-group>. <article-title>Situation of SARS-CoV-2 infection in China</article-title> . Available online at: <uri xlink:href="https://www.Chinacdc.cn/jksj/xgbdyq/202503/t20250324_305223.html">https://www.Chinacdc.cn/jksj/xgbdyq/202503/t20250324_305223.html</uri> (Accessed <date-in-citation content-type="access-date">May 8, 2025</date-in-citation>).</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nikolich-Zugich</surname><given-names>J</given-names></name><name><surname>Knox</surname><given-names>KS</given-names></name><name><surname>Rios</surname><given-names>CT</given-names></name><name><surname>Natt</surname><given-names>B</given-names></name><name><surname>Bhattacharya</surname><given-names>D</given-names></name><name><surname>Fain</surname><given-names>MJ</given-names></name></person-group>. <article-title>SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes</article-title>. <source>Geroscience</source>. (<year>2020</year>) <volume>42</volume>:<page-range>505&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11357-020-00186-0</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bencivenga</surname><given-names>L</given-names></name><name><surname>Rengo</surname><given-names>G</given-names></name><name><surname>Varricchi</surname><given-names>G</given-names></name></person-group>. <article-title>Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition</article-title>. <source>Geroscience</source>. (<year>2020</year>) <volume>42</volume>:<page-range>1089&#x02013;92</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11357-020-00218-9</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Canaday</surname><given-names>DH</given-names></name><name><surname>Carias</surname><given-names>L</given-names></name><name><surname>Oyebanji</surname><given-names>OA</given-names></name><name><surname>Keresztesy</surname><given-names>D</given-names></name><name><surname>Wilk</surname><given-names>D</given-names></name><name><surname>Payne</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Reduced BNT162b2 messenger RNA vaccine response in severe acute respiratory syndrome coronavirus 2 (SARS-coV-2)-naive nursing home residents</article-title>. <source>Clin Infect Dis</source>. (<year>2021</year>) <volume>73</volume>:<page-range>2112&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/cid/ciab447</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Collier</surname><given-names>DA</given-names></name><name><surname>Ferreira</surname><given-names>I</given-names></name><name><surname>Kotagiri</surname><given-names>P</given-names></name><name><surname>Datir</surname><given-names>RP</given-names></name><name><surname>Lim</surname><given-names>EY</given-names></name><name><surname>Touizer</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>596</volume>:<page-range>417&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-021-03739-1</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>The impact of age difference on the efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>758294</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.758294</pub-id>
<pub-id pub-id-type="pmid">34938287</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lang</surname><given-names>PO</given-names></name><name><surname>Govind</surname><given-names>S</given-names></name><name><surname>Bokum</surname><given-names>AT</given-names></name><name><surname>Kenny</surname><given-names>N</given-names></name><name><surname>Matas</surname><given-names>E</given-names></name><name><surname>Pitts</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Immune senescence and vaccination in the elderly</article-title>. <source>Curr Top Med Chem</source>. (<year>2013</year>) <volume>13</volume>:<page-range>2541&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2174/15680266113136660181</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soegiarto</surname><given-names>G</given-names></name><name><surname>Wulandari</surname><given-names>L</given-names></name><name><surname>Purnomosari</surname><given-names>D</given-names></name><name><surname>Dhia Fahmita</surname><given-names>K</given-names></name><name><surname>Ikhwan Gautama</surname><given-names>H</given-names></name><name><surname>Tri Hadmoko</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2</article-title>. <source>Vaccine</source>. (<year>2022</year>) <volume>40</volume>:<page-range>4046&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2022.05.059</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashrafian</surname><given-names>F</given-names></name><name><surname>Bagheri Amiri</surname><given-names>F</given-names></name><name><surname>Bavand</surname><given-names>A</given-names></name><name><surname>Zali</surname><given-names>M</given-names></name><name><surname>Sadat Larijani</surname><given-names>M</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name></person-group>. <article-title>A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between individuals with comorbidities and the normal population</article-title>. <source>Vaccines (Basel)</source>. (<year>2023</year>) <volume>11</volume>(<issue>8</issue>):<page-range>1376</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines11081376</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Liang</surname><given-names>YM</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>LB</given-names></name><etal/></person-group>. <article-title>Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China</article-title>. <source>J Med Virol</source>. (<year>2024</year>) <volume>96</volume>:<elocation-id>e29640</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/jmv.29640</pub-id>
<pub-id pub-id-type="pmid">38699969</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Jian</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Yisimayi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution</article-title>. <source>Nature</source>. (<year>2023</year>) <volume>614</volume>:<page-range>521&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-05644-7</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wajnberg</surname><given-names>A</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Firpo</surname><given-names>A</given-names></name><name><surname>Altman</surname><given-names>DR</given-names></name><name><surname>Bailey</surname><given-names>MJ</given-names></name><name><surname>Mansour</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Robust neutralizing antibodies to SARS-CoV-2 infection persist for months</article-title>. <source>Science</source>. (<year>2020</year>) <volume>370</volume>:<page-range>1227&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abd7728</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>4984</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-021-25312-0</pub-id>
<pub-id pub-id-type="pmid">34404803</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Faliti</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</article-title>. <source>Science</source>. (<year>2021</year>) <volume>371</volume>(<issue>6529</issue>):<elocation-id>eabf4063</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id>
<pub-id pub-id-type="pmid">33408181</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rydyznski Moderbacher</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>996</fpage>&#x02013;<lpage>1012 e1019</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id>
<pub-id pub-id-type="pmid">33010815</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title>. <source>Nat Med</source>. (<year>2020</year>) <volume>26</volume>:<page-range>842&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Acute SARS-coV-2 infection impairs dendritic cell and T cell responses</article-title>. <source>Immunity</source>. (<year>2020</year>) <volume>53</volume>:<fpage>864</fpage>&#x02013;<lpage>877 e865</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.026</pub-id>
<pub-id pub-id-type="pmid">32791036</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fong</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Poon</surname><given-names>RW</given-names></name><name><surname>Chan</surname><given-names>BP</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study</article-title>. <source>EBioMedicine</source>. (<year>2023</year>) <volume>88</volume>:<elocation-id>104446</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104446</pub-id>
<pub-id pub-id-type="pmid">36706582</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taira</surname><given-names>N</given-names></name><name><surname>Toguchi</surname><given-names>S</given-names></name><name><surname>Miyagi</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Tomori</surname><given-names>H</given-names></name><name><surname>Oshiro</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals</article-title>. <source>Clin Immunol Commun</source>. (<year>2022</year>) <volume>2</volume>:<fpage>6</fpage>&#x02013;<lpage>11</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.clicom.2021.12.001</pub-id>
<pub-id pub-id-type="pmid">38621014</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022</article-title>. <source>J Infect</source>. (<year>2023</year>) <volume>87</volume>:<page-range>413&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jinf.2023.08.010</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bond</surname><given-names>K</given-names></name><name><surname>Nicholson</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>SM</given-names></name><name><surname>Karapanagiotidis</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Evaluation of serological tests for SARS-coV-2: implications for serology testing in a low-prevalence setting</article-title>. <source>J Infect Dis</source>. (<year>2020</year>) <volume>222</volume>:<page-range>1280&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/infdis/jiaa467</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Retnakumar</surname><given-names>SV</given-names></name><name><surname>Chauvin</surname><given-names>C</given-names></name><name><surname>Bayry</surname><given-names>J</given-names></name></person-group>. <article-title>The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases</article-title>. <source>Pharmacol Ther</source>. (<year>2023</year>) <volume>245</volume>:<elocation-id>108399</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2023.108399</pub-id>
<pub-id pub-id-type="pmid">37001736</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Jiao</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors</article-title>. <source>J Med Virol</source>. (<year>2023</year>) <volume>95</volume>:<elocation-id>e28641</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/jmv.28641</pub-id>
<pub-id pub-id-type="pmid">36890632</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uraki</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Furusawa</surname><given-names>Y</given-names></name><name><surname>Yamayoshi</surname><given-names>S</given-names></name><name><surname>Iwatsuki-Horimoto</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB</article-title>. <source>Lancet Infect Dis</source>. (<year>2023</year>) <volume>23</volume>:<page-range>30&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00816-7</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination(1)</article-title>. <source>Emerg Microbes Infect</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>2249121</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/22221751.2023.2249121</pub-id>
<pub-id pub-id-type="pmid">37668156</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2023</year>) <volume>8</volume>:<fpage>252</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41392-023-01495-4</pub-id>
<pub-id pub-id-type="pmid">37336889</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Nie</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>WB</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1</article-title>. <source>Emerg Microbes Infect</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>2225638</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/22221751.2023.2225638</pub-id>
<pub-id pub-id-type="pmid">37313604</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yisimayi</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jian</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting</article-title>. <source>Nature</source>. (<year>2024</year>) <volume>625</volume>:<page-range>148&#x02013;56</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-023-06753-7</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esmaeilzadeh</surname><given-names>A</given-names></name><name><surname>Ebrahimi</surname><given-names>F</given-names></name><name><surname>Jahani Maleki</surname><given-names>A</given-names></name><name><surname>Siahmansouri</surname><given-names>A</given-names></name></person-group>. <article-title>EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19</article-title>. <source>Infection</source>. (<year>2024</year>) <volume>52</volume>:<page-range>337&#x02013;43</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s15010-023-02146-0</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jara</surname><given-names>A</given-names></name><name><surname>Undurraga</surname><given-names>EA</given-names></name><name><surname>Zubizarreta</surname><given-names>JR</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Pizarro</surname><given-names>A</given-names></name><name><surname>Acevedo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study</article-title>. <source>Lancet Glob Health</source>. (<year>2022</year>) <volume>10</volume>:<page-range>e798&#x02013;806</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S2214-109X(22)00112-7</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants</article-title>. <source>Nature</source>. (<year>2022</year>) <volume>603</volume>:<page-range>919&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41586-022-04466-x</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Garibaldi</surname><given-names>BT</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Osevala</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Aging in COVID-19: Vulnerability, immunity and intervention</article-title>. <source>Ageing Res Rev</source>. (<year>2021</year>) <volume>65</volume>:<elocation-id>101205</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.arr.2020.101205</pub-id>
<pub-id pub-id-type="pmid">33137510</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duggal</surname><given-names>NA</given-names></name></person-group>. <article-title>Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions</article-title>. <source>Biogerontology</source>. (<year>2018</year>) <volume>19</volume>:<page-range>481&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10522-018-9771-7</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cancro</surname><given-names>MP</given-names></name></person-group>. <article-title>Age-associated B cells</article-title>. <source>Annu Rev Immunol</source>. (<year>2020</year>) <volume>38</volume>:<page-range>315&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-092419-031130</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frasca</surname><given-names>D</given-names></name></person-group>. <article-title>Senescent B cells in aging and age-related diseases: Their role in the regulation of antibody responses</article-title>. <source>Exp Gerontol</source>. (<year>2018</year>) <volume>107</volume>:<page-range>55&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.exger.2017.07.002</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>MC</given-names></name><name><surname>Ramonell</surname><given-names>RP</given-names></name><name><surname>Nguyen</surname><given-names>DC</given-names></name><name><surname>Cashman</surname><given-names>KS</given-names></name><name><surname>Saini</surname><given-names>AS</given-names></name><name><surname>Haddad</surname><given-names>NS</given-names></name><etal/></person-group>. <article-title>Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19</article-title>. <source>Nat Immunol</source>. (<year>2020</year>) <volume>21</volume>:<page-range>1506&#x02013;16</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-020-00814-z</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bartleson</surname><given-names>JM</given-names></name><name><surname>Radenkovic</surname><given-names>D</given-names></name><name><surname>Covarrubias</surname><given-names>AJ</given-names></name><name><surname>Furman</surname><given-names>D</given-names></name><name><surname>Winer</surname><given-names>DA</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name></person-group>. <article-title>SARS-coV-2, COVID-19 and the ageing immune system</article-title>. <source>Nat Aging</source>. (<year>2021</year>) <volume>1</volume>:<page-range>769&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s43587-021-00114-7</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Acharya</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Paul</surname><given-names>AM</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Gate</surname><given-names>D</given-names></name><name><surname>Lowery</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate west nile virus clearance</article-title>. <source>J Virol</source>. (<year>2017</year>) <volume>91</volume>(<issue>1</issue>):<elocation-id>e01529-16</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/JVI.01529-16</pub-id>
<pub-id pub-id-type="pmid">27795421</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Poon</surname><given-names>VK</given-names></name><name><surname>Leung</surname><given-names>VH</given-names></name><etal/></person-group>. <article-title>A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection</article-title>. <source>Cell Mol Immunol</source>. (<year>2011</year>) <volume>8</volume>:<page-range>462&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/cmi.2011.38</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>WT</given-names></name><name><surname>Yao</surname><given-names>XT</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>DK</given-names></name></person-group>. <article-title>The protective and pathogenic roles of IL-17 in viral infections: friend or foe</article-title>? <source>Open Biol</source>. (<year>2019</year>) <volume>9</volume>:<elocation-id>190109</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1098/rsob.190109</pub-id>
<pub-id pub-id-type="pmid">31337278</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spitaels</surname><given-names>J</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name></person-group>. <article-title>In fl uenza and Memory T Cells: How to Awake the Force</article-title>. <source>Vaccines (Basel)</source>. (<year>2016</year>) <volume>4</volume>:<fpage>33</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/vaccines4040033</pub-id>
<pub-id pub-id-type="pmid">27754364</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>RX</given-names></name><name><surname>Boland</surname><given-names>GJ</given-names></name><name><surname>van Hattum</surname><given-names>J</given-names></name><name><surname>de Gast</surname><given-names>GC</given-names></name></person-group>. <article-title>Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination</article-title>. <source>World J Gastroenterol</source>. (<year>2004</year>) <volume>10</volume>:<page-range>260&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3748/wjg.v10.i2.260</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kunzli</surname><given-names>M</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group>. <article-title>CD4(+) T cell memory</article-title>. <source>Nat Immunol</source>. (<year>2023</year>) <volume>24</volume>:<page-range>903&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41590-023-01510-4</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Farrar</surname><given-names>JD</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ranganath</surname><given-names>S</given-names></name><name><surname>Asnagli</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Signaling and transcription in T helper development</article-title>. <source>Annu Rev Immunol</source>. (<year>2000</year>) <volume>18</volume>:<page-range>451&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.18.1.451</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graham</surname><given-names>MB</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Giltinan</surname><given-names>D</given-names></name><name><surname>Braciale</surname><given-names>VL</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Braciale</surname><given-names>TJ</given-names></name></person-group>. <article-title>Response to influenza infection in mice with a targeted disruption in the interferon gamma gene</article-title>. <source>J Exp Med</source>. (<year>1993</year>) <volume>178</volume>(<issue>5</issue>):<page-range>1725&#x02013;32</page-range>. doi:&#x000a0;10.1084 jem.178.5.1725
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaplin</surname><given-names>DD</given-names></name></person-group>. <article-title>Overview of the immune response</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2010</year>) <volume>125</volume>:<fpage>S3</fpage>&#x02013;<lpage>23</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.980</pub-id>
<pub-id pub-id-type="pmid">20176265</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gladstone</surname><given-names>DE</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Mooney</surname><given-names>K</given-names></name><name><surname>Karaba</surname><given-names>AH</given-names></name><name><surname>D'Alessio</surname><given-names>FR</given-names></name></person-group>. <article-title>Regulatory T cells for treating patients with COVID-19 and acute respiratory distress syndrome: two case reports</article-title>. <source>Ann Intern Med</source>. (<year>2020</year>) <volume>173</volume>:<page-range>852&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7326/L20-0681</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortezaee</surname><given-names>K</given-names></name><name><surname>Majidpoor</surname><given-names>J</given-names></name></person-group>. <article-title>Cellular immune states in SARS-CoV-2-induced disease</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1016304</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1016304</pub-id>
<pub-id pub-id-type="pmid">36505442</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Govender</surname><given-names>M</given-names></name><name><surname>Hopkins</surname><given-names>FR</given-names></name><name><surname>Goransson</surname><given-names>R</given-names></name><name><surname>Svanberg</surname><given-names>C</given-names></name><name><surname>Shankar</surname><given-names>EM</given-names></name><name><surname>Hjorth</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>T cell perturbations persist for at least 6 months following hospitalization for COVID-19</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>931039</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.931039</pub-id>
<pub-id pub-id-type="pmid">36003367</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2021</year>) <volume>148</volume>:<fpage>1481</fpage>&#x02013;<lpage>1492 e1482</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2021.09.008</pub-id>
<pub-id pub-id-type="pmid">34536418</pub-id>
</mixed-citation></ref></ref-list></back></article>